“…The fact that many demyelinated lesions contain OPCs that do not differentiate has prompted efforts to identify strategies to promote oligodendrocyte differentiation. Indeed, recent unbiased phenotypic screens have led to the identification of several hit compounds that promote oligodendrocyte differentiation in vitro ( Deshmukh et al, 2013 ; Joubert et al, 2010 ; Mei et al, 2014 ; Mei et al, 2016 ; Najm et al, 2015 ; Peppard et al, 2015 ; Porcu et al, 2015 ). A number of these hits have been validated in vivo ( Cole et al, 2017 ), and one, clemastine, has even shown efficacy in improving optic nerve function in patients with MS ( Green et al, 2017 ).…”